Anavex Life Sciences (US:AVXL) Globenewswire·2026-01-06 17:40Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Developments - On November 14, 2025, Anavex announced a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning the Marketing Authorisation Application (MAA) for blarcamesine [3]. - Following this announcement, Anavex's stock price dropped by $2.05 per share, representing a decline of 35.94%, closing at $3.65 per share on the same day [3]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for the rights of victims of securities fraud and corporate misconduct [4]. - The firm has a track record of recovering multimillion-dollar damages awards for class members [4].